Jefferies analyst Kelly Shi maintained a Buy rating on Agenus (AGEN – Research Report) on July 1 and set a price target of $6.00. The company’s shares closed last Monday at $1.52.
Shi covers the Healthcare sector, focusing on stocks such as Agenus, CTI BioPharma, and PTC Therapeutics. According to TipRanks, Shi has an average return of -8.5% and a 38.67% success rate on recommended stocks.
Agenus has an analyst consensus of Strong Buy, with a price target consensus of $8.08, which is a 431.58% upside from current levels. In a report released on July 3, B.Riley Financial also reiterated a Buy rating on the stock with a $8.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $3.31 and a one-year low of $1.28. Currently, Agenus has an average volume of 5.66M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
Read More on AGEN:
